Trade TVTX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Travere Therapeutics, Inc. (TVTX) is trading at US$66.12, down 2.07% today as of Aug 28, 12:01 EDT. The company has a market capitalisation of US$6.19B. Over the past 52 weeks, TVTX has traded between US$17.27 and US$67.85. On Syfe you can trade TVTX with $0 commission and add it to your watchlist.
| Previous close | US$67.52 |
|---|---|
| Market cap | US$6.19B |
| P/E ratio | 32.02 |
| 52-week range | US$17.27 – US$67.85 |
| Volume | 893.41K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Year: 2003
Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027
Jul 10, 10:16 AM · MT Newswires
Travere Therapeutics, Inc. (TVTX) stock is trading at US$66.12, -2.07% from the previous close of US$67.52.
The market cap for Travere Therapeutics, Inc. (TVTX) stock is approximately US$6.19B.
The price-to-earnings ratio for Travere Therapeutics, Inc. (TVTX) is 32.02, based on the latest reported earnings.
The 52-week high for Travere Therapeutics, Inc. (TVTX) stock is US$67.85.
The 52-week low for Travere Therapeutics, Inc. (TVTX) stock is US$17.27.
Travere Therapeutics, Inc. (TVTX) does not currently pay a dividend.
Stay on top of TVTX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
